INTRODUCTION
Previous studies have defined the role of the reticuloendothelial system in the clearance of soluble immune complexes infused into the circulation (1) (2) (3) (4) (5) . It was shown that the bulk (up to 50%) of immune complexes was taken up by the liver, (2) , indicating that the reticuloendothelial system serves as an important buffer against these potentially phlogistic substances. The reticuloendothelial system was also shown to be subject to saturation when it was presented with increasing amounts of immune complexes (3) . Furthermore, when uptake of immune complexes by the liver and spleen was reduced, the amount deposited in the glomerulus was correspondingly increased (4, 5) . Thus, alterations in reticuloendothelial system function may be important in modulating the localization of immune complexes in the kidney. Many forms of human and experimental nephritis arise from the entrapment of circulating immune complexes in the kidney. Such complexes may be presumed to have escaped processing by the reticuloendothelial system, either because the latter is saturated or defective. It is logical to propose that activation of the reticuloendothelial system under these circumstances may lead to enhanced clearance of soluble immune complexes by the liver, spleen, and other phagocytic cells, thereby decreasing the impact of such complexes on the kidney. The present study was designed to determine if such an effect would be achieved, using the passive model of serum sickness nephritis, and activating the reticuloendothelial system by Corynebacterium parvum.
METHODS
Production and isolation of antibody. Bovine albumin (Miles Laboratories, Inc., Ames Div. Elkhart, Ind.) was dissolved in 0.15 M NaCl at a concentration of 10 mg/ml and emulsified with an equal volume of complete Freund's adjuvant. Rabbits were immunized by intramuscular injection of 10 mg of the antigen; booster doses were given 2 wk after the initial injection, and thereafter at 4-wk intervals. Animals Purified anti-bovine serum albumin (anti-BSA)' was isolated by means of an immunoadsorbent column, using a modification of previously described techniques (6, 7) . In brief, 0.3 ml of glutaraldehyde (final concentration 50% vol/vol) was added to 30 ml of BSA (40 mg/ml) with stirring. The mixture was allowed to settle at room temperature until a gel had formed. A volume of 30 ml of phosphate-buffered saline (PBS) was added to the gel, which was broken up by homogenizing for 10-15 s with a Polytron (Brinkmann Instruments, Inc., Westbury, N. Y.) at the lowest speed setting. A slurry of Sephadex was prepared by adding 75 ml of PBS, pH 7.4, to 15 g of coarse Sephadex G-25 (Pharmacia Fine Chemicals, Div. Pharmacia, Inc., Piscataway, N. J.). This slurry was mixed thoroughly with the homogenized gel. A 60 x 170-mm glass column was packed with the mixture, washed with 100 ml glycine buffer, pH 2.8, followed by PBS, pH 7.4 until the effluents gave a pH >7. An aliquot of 40 ml rabbit serum was decomplemented by heating at 56°C x 30 min, diluted with 80 ml of PBS, pH 7.4, and run through the column at 0.5 ml/min. The column was washed with 600-800 ml of PBS pH 7.4 until optical density at 280 nm was <0.03. Specific anti-BSA antibody was eluted from the column with 0.1 M glycine buffer pH 2.8. Fractions containing protein were pooled, pH adjusted to 7.4 using 0.1 M NaOH, and dialyzed against 0.15 M NaCl. After dialysis, the protein was concentrated through an Amicon XM-100 filter (Amicon Corp., Scientific Sys. Div., Lexington, Mass.). All procedures were done at 4°C. Monomeric anti-BSA antibody was obtained by ultracentrifugation at 100,000g x 90 min with collection ofthe protein in the upper two-thirds ofthe specimen. Antibody was stored at -70°C until used. Purity of the antibody was established by immunoelectrophoresis. Sucrose density gradient ultracentrifugation (see below) of labeled antibody showed it to have a sedimentation coefficient of 7S. Trace labeling with 125I (New England Nuclear, Boston, Mass.) ofthe antibody (sp act 1 ,uCi/mg) was done by the chloramine-T method (8) .
Preparation of immune complexes. This was done by a previously reported technique (9) . Quantitative precipitin curves were constructed using BSA, and monomeric 1251_ anti-BSA antibody to determine the point of equivalence. Immune precipitates were prepared at equivalence; incubation was done at 370C x 1 h followed by 40C x 24 h. The precipitates were washed three times with cold normal saline, and suspended in the same solution. Five times excess of antigen was added to the suspension and pH lowered to 2.4 by the stepwise addition of 0.1 N HCI. Precipitates were completely solubilized at this pH. The pH was then readjusted to 7.4 with 0.1 N NaOH. Soluble immune complexes were stored at 4°C for 48 h and centrifuged at 10,000 rpm x 30 min before use.
Sucrose density gradient ultracentrifugation analysis. The size of complexes was measured by sucrose density gradient ultracentrifugation analysis using previously reported techniques (10) . Serum samples obtained from animals at the end of 3 h were diluted 1:10 with PBS before analysis.
In brief, 200 ,ul of a sample was applied to 10-40% sucrose gradients and ultracentrifuged at 35,000 rpm for 16 h at 40C using an SW50.1 rotor in a Spinco ultracentrifuge (Model L2) (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.). Sedimentation coefficients were estimated by the method of Martin and Ames (11) , using the markers BSA human IgG, Clq, and IgM. Fractionated material showed two peaks, a 7S peak (presumed to be unreacted anti-BSA because ultracentrifugation analysis of complexes formed by 1Abbreviations used in this paper: BSA, bovine serum albumin; PBS, phosphate-buffered saline. using labeled albumin did not show any label in the 7S region, thereby excluding the possibility that this represented small sized immune complexes) and another peak containing 13 To determine the effect of C. parvum injection on renal function, measurements of serum creatinine were done on sera obtained from a group (five animals each) of control and C. parvum-treated mice using an autoanalyzer method. The geometric mean serum creatining (mean±+SD) of the controls and C. parvum-treated mice were 0.38 mg/100 ml (0.33-0.43 mg/100 ml) and 0.36 mg/100 (0.30-0.42 mg/100 ml), respectively (t = 0.63, P < 0.3).
Specific organ uptake ofimmune complexes. The specific localization of BSA-l25I-anti-BSA complexes in the liver and spleen was determined 3 h after the injection of complexes. Mice received an injection of 200 tg of human monomeric 131I-IgG as an intravascular blood marker 5 min before killing. The I251 and 1311 counts per min in the organs were determined and the l25I-specific uptake was calculated as follows:
25I-specific uptake = 125I counts per minute/organ 131 counts per minute/organ 1311 counts per minute/milliliter blood x 125k counts per minute/milliliter blood.
In separate experiments using three control and an equal number ofC. parvum-treated mice, peritoneal washings were obtained at 3 h and counted for radioactivity.
The concentration of antibody in the organ was calculated from the specific activity of the antibody protein.
Specific localization of immune complexes in isolated glomeruli. Mouse glomeruli were isolated by the following procedure. Kidneys were removed from mice during killing. Cortices were dissected from medullae, and cortical tissue pressed through a 200-mesh stainless steel sieve (74 ,Am pore Diam), and passaged material suspended in PBS. The suspension was forced through a 25-gauge needle and allowed to stand in ice for 30 min. The supernatant was suctioned off and the sediment resuspended in PBS and centrifuged at 1,000 rpm x 5 min. The supemate was discarded and resuspended in 0.5 ml PBS and layered on top of a 72% sucrose solution and centrifuged at 1,000 rpm for 15 min. The resultant pellet was suspended in 0.2 ml PBS, and passed once more through the 25-gauge needle. Glomeruli were stained with a 0.1% solution oftoluidine blue and counted in a hemacytometer. The preparations contained -80% glomeruli with some tubules. Glomeruli from four kidneys were pooled and counted for I251 and 131I radioactivity. l25I-anti-BSA bound to glomeruli was determined after correction for blood counts (using 1311-IgG counts as the blood marker) using the formula previously described. In the first series of experiments, one kidney from each animal was processed for isolation of glomeruli to quantitate the amount ofantibody bound, and the other kidney processed for histologic analysis. A second series of experiments was done for the specific purpose of quantitating the amount of immune complexes localized in the glomeruli. Control and C. parvum-treated groups consisted of four animals in each group. A blood sample was obtained at 5 min to ensure that comparable amounts of complexes had been infused into the animals; these mice were killed and kidneys processed as described.
Histologic examination of kidneys. Cortical wedges of kidney tissue were obtained from killed animals and processed for fluorescence and light microscopy by previously described techniques (12) . For fluorescence microscopy, a fluorescein-conjugated goat anti-rabbit IgG antiserum (N. L. Cappel Laboratories, Cochranville, Pa.) was used; monospecificity of antisera was monitored by immunoelectrophoresis. A semiquantitative scale of grading the extent of fluorescent deposits was used, with a scale from 0 to 4, each unit indicating one quadrant of a glomerulus having a significant amount of IgG deposited. Previous studies have validated this method of scoring (12) . All comparisons were done independently by two observers, with no knowledge of the states of the animals from which the kidneys were obtained.
In vitro experiments using peritoneal macrophage cultures. The methods for harvesting and maintaining mouse peritoneal macrophages have previously been reported (13) . The technique of assessing Fc receptor function is that of Bianco (14) , previously reported in detail (14) . In brief, immune complexes were prepared by incubating 1 
RESULTS
Blood levels of 7S and 13.6S fractions. Analysis by sucrose density gradient ultracentrifugation revealed that injected BSA-anti-BSA material resolved into two peaks (Fig. 1) , a 7S peak and a peak containing 13.6S and larger complexes (designated the 13.6S peak). Ultracentrifugation analysis showed that serum samples obtained at 3 and 12 h from C. parvum-treated mice contained a reduced amount of 13.6S material compared with untreated animals, indicating greater removal of 13 .6S fractions (Fig. 1) . The calculated amount of the two fractions at 5 min, at 3 h, and at 12 h, are given in Table I and Table III . Comparable amounts of radiolabeled material were administered into the two groups of mice, as indicated by the concentrations of 125I-anti-BSA (7S + 13.6S fractions-see Tables I and  III) . At 3 h, the levels oftotal 125I-anti-BSA (7S + 13.6S fractions) and of 13.6S fractions were significantly lower in C. parvum-treated mice compared with control animals ( Fig. 2 Fig. 3 and Table III) . Additionally, at 12 h, levels of 7S fractions of C. parvumtreated animals showed a small but significant decrease compared with levels in control animals (Table III) .
Blood levels of degraded 1251-anti-BSA antibody.
The concentrations of degraded 125I-anti-BSA antibody at 3 and at 12 h are given in Tables I and III and show that the amount of labeled antibody degraded by C. parvum-treated animals was significantly increased compared with that of controls; mean levels in control and C. parvum-treated animals being 39 and 93 ,g/ml, respectively at 3 h; (t = 2.86, P < 0.02, Table I ); by 12 h the differences were even more pronounced being 23 ug/ml for controls and 97 ,ig/ml for C. parvuminjected animals (t = 7.92, P < 0.001, Table III 2 Blood levels (mean+SE) of 125I-anti-BSA and its fractions at 5 min and at 3 h in control and C parvum-treated mice. An aliquot of BSA-l25I-anti-BSA containing 3 mg antibody was given intravenously into the mice. By sucrose density gradient ultracentrifugation analysis the distribution of 7S and 13.6S fractions was obtained and the concentration of each calculated. At 3 h, the levels of total (7S + 13.6S) 125I-anti-BSA material and 13.6S fractions were significantly lower in C. parvum-treated mice compared with normal. even more pronounced, mean uptake by this organ being increased by about five times that of control mice at 3 h and being increased by almost nine times at 12 h (Tables II and III) .
The weights of the liver and spleen were obtained in the two groups of mice at 12 h. The mean weights (+SD) of control and C. parvum-treated livers were 950+78 mg and 1,556+248 mg, respectively. The mean weights (+ SD) of spleens were 76+17 mg and 327+97 mg for control and experimental groups, respectively. The mean uptake of immune complexes per mg liver tissue was identical in both control and C. parvumtreated animals, being 0.29 ,ug/mg liver tissue. However, uptake of immune complexes per milligram splenic tissue was higher in C. parvum mice than in control mice, being 0.15 ug/mg splenic tissue compared with 0.08 ,ug/mg splenic tissue (t = 4.9, P < 0.001).
Using glomerular isolation techniques, the amount of 125I-anti-BSA bound to glomeruli was quantitated and was found to be reduced in C. parvum-treated animals being 91 ng/8,000 glomeruli compared with 180 ng/8,000 glomeruli in normal mice (t = 6.54, P < 0.01) Table II . At 12 h, immune complexes could be not detected in kidneys ofeither control orC. parvumtreated animals. This finding was probably related to the markedly reduced blood levels of 13.6S fractions.
To exclude the possibility that differences in blood levels could be attributable to differences in peritoneal content of immune complexes, peritoneal washings were counted. The mean concentrations of 125I-anti-BSA (+ SD) ofcontrol and C. parvum-treated mice were 4±1 ,ug and 18+ 1.7 ,g, respectively (t = 12.1, P < 0.01). Although the differences were significant, it should be noted that the absolute amount constituted only a minute fraction of the quantity infused.
Histologic examination. By using light microscopy, there were only minor mesangial changes that could not be readily quantitated. The differences were more evident by fluorescence microscopy, and semiquan-fluorescent appearances of representative glomeruli titative grading showed significantly increased amounts from the two groups of animals are depicted in Fig. 4 phages of control and C. parvum-treated mice in triplicate cultures were 537 (+68) and 1,054 (+78), respectively (t = 5.0, P < 0.01).
DISCUSSION
The present study provides data which show that activation ofthe reticuloendothelial system by an agent such as C. parvum leads to reduced deposition of immune complexes in the kidney in the model of passive serum sickness nephritis in the mouse. Decreased localization of complexes in the kidney of C. parvum-treated mice was demonstrated by two methods with concordant results: by quantitation of radiolabeled complexes bound to isolated glomeruli, and by immunofluorescent methods visualizing decreased amounts of mesangial deposits (by comparison to untreated mice). This effect was achieved by two mechanisms: enhanced uptake of immune complexes by the liver and the spleen, and augmented degradation as determined by increased concentrations of TCAsoluble radioactive material in the circulation. The net effect was to diminish the plasma level of immune complexes with beneficial consequences to the kidney. The mechanism of enhanced uptake of immune complexes by the liver appears to be different from that by the spleen. The amount ofimmune complexes taken up by the liver of C. parvum-treated mice increased pari passu with its weight, suggesting that increased delivery may be a mechanism. In the case ofthe spleen, the quantity of complexes taken up increased more than could be accounted for by the increase in weight, suggesting that there may be additional mechanisms such as enhanced Fc receptor-mediated functional activity. Insight into the mechanism of augmented uptake of immune complexes by the (17, 18) . The enhancing effect of complement has been demonstrated and shown to be due to increased uptake of complexes by these cells (18) . The mechanisms for increased in vivo degradation of immune complexes shown in this study remain to be elucidated.
The results of the current investigation extend the observations of Ford (19) (21) have reported in abstract form the finding that zymosan activation of the reticuloendothelial system leads to reduced deposition of soluble aggregates in the rat kidney. However, zymosan also gives rise to complement depletion, and this may potentially affect the ability of macrophages to degrade immune complexes in view of the evidence for an enhancing effect of complement in the processing of soluble complexes, and the alteration of receptor function of such macrophages (16, 18) .
The significance of our observations relates to the potential use of such immunostimulants as a modality in the treatment of various forms of human immune complex-mediated nephritis. Immune complexes have been detected in the sera of patients with diffuse proliferative gloimierulonephritis, lupus nephritis, membranoproliferative glomerulonephritis, and other forms of nephritis (22) (23) (24) . Studies of reticuloendothelial function in some ofthese forms of human renal disease have also shown impaired splenic clearance ofimmune complexes in these patients (25, 26) . It is uncertain if this impairment is a primary defect, or ifit is a reflection of saturation of the reticuloendothelial system by the complexes (of interest, studies of Finbloom and Plotz (27) and by Knutson et al. (28) have shown that the ability of NZB/W female mice to clear soluble immune complexes was unimpaired). Regardless of the mechanism for this event, it appears reasonable to suppose that activation of the reticuloendothelial system may exert a beneficial effect on the kidney by the mechanisms described in this model. An additional salutory effect may be inferred from recent observations that point to the monocyte as being important in removal of tissue immune complexes (29) . Currently, macrophage and reticuloendothelial system activating agents such as C. parvum and Bacille Calmette-Gu6rin are being used in the therapy of some forms of human cancer, and underline the potential applicability of the results ofthis study to the management of patients with immune complex mediated renal disease. It is recognized that the use of such immunostimulants may give rise to an enhanced antibody response, which may limit their usefulness. However, it is expected that the functional capacity of the reticuloendothelial system will also be increased, and allow it to deal effectively with the increased loads of immune complexes; studies of saturability of the reticuloendothelial system under these conditions are in progress to determine if this is the case.
